New treatment method helped brain process chemicals similar to marijuana in animal study TUESDAY, Sept. 25 (HealthDay News) -- Scientists in search of greater understanding of Fragile X syndrome, a genetic condition tied to [...]
The NFXF is pleased to see the media attention surrounding the latest news resulting from clinical trials for Fragile X syndrome treatments. Two members of the NFXF’s Scientific and Clinical Advisory Committee, Dr. Randi Hagerman, the NFXF’s co-founder, and Dr. Elizabeth Berry-Kravis, also a member of the NFXF’s Board of Directors, have been receiving prominent mention. The NFXF has been pleased to be able to assist its corporate partner, Seaside Therapeutics, with recruitment for this trial and others.
NFXF Scientific & Clinical Advisory Committee member Dr. Elizabeth Berry-Kravis had the following to share about the ScienceDaily report recently published. This news article is a little confusing when it implies that treatments for Fragile [...]
Roche and Seaside Therapeutics announced today that they have entered into a collaboration to develop disease modifying treatments for Fragile X syndrome (FXS) and autism spectrum disorders (ASD), both neurodevelopmental disorders
Our latest podcast features Robert Miller of the National Fragile X Foundation and representatives of the the major pharmaceutical companies involved in ongoing Fragile X Clinical Trials. We have Dr. Paul Wang, Vice President, Clinical Development of [...]
New Haven Conn., April 18, 2012 /PRNewswire/ -- JS Genetics announces the launch of XCAT-FX, its propitiatory buccal swab test for the detection of Fragile X syndrome. Fragile X syndrome is the most common cause [...]
Robert Miller Executive Director National Fragile X Foundation Readers should know that the researchers involved with this study, and their affiliated institutions and companies, are highly regarded and well-known in the Fragile X [...]
New Patent Complements STX209 Orphan Drug Designation for Fragile X Syndrome CAMBRIDGE, Mass., Mar 27, 2012 (BUSINESS WIRE) -- Seaside Therapeutics, Inc. announced today that the United States Patent and Trademark Office (USPTO) has [...]
Abstract Fragile X syndrome is the most common cause of inherited intellectual impairment and the most common single-gene cause of autism. Individuals with Fragile X syndrome present with a neurobehavioural phenotype that includes selective deficits [...]
The National Institutes of Health has developed a research plan to advance the understanding of Fragile X syndrome and its associated conditions, Fragile X-associated tremor/ataxia syndrome and Fragile X-associated primary ovarian insufficiency. Fragile X syndrome [...]
